Drugmaker Eli Lilly (NYSE: LLY) hasn't been exempt from the recent market pullback, but its stock shot higher following the ...

Eli Lilly's Mounjaro (Tirzepatide), a dual GIP and GLP-1 receptor agonist, has launched in India, generating buzz as a weight ...

The once-daily pill, currently under investigation, is being studied for adults with type 2 diabetes who are not on any ...

A once-weekly dose of tirzepatide (Mounjaro) can lead to significant, sustained weight loss for up to 3 years in adults with ...

"Women coming off weight loss injections in midlife need to be particularly strategic about their approach," Rachael adds. "The hormonal shifts of midlife can reduce muscle protein synthesis by up to ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

CEO Dave Ricks said Friday that the company will make its planned GLP-1 weight-loss pill in the U.S. amid President Donald ...

A daily weight loss pill that works like breakthrough fat jab Ozempic could be available in the UK as early as next year.

Eli Lilly's new oral weight loss pill, orforglipron, shows promise in Phase 3 trials, offering a convenient alternative to ...

Diabetics given the pill called orforglipron lost 16 pounds, or 7.9% of their body weight, over a 40-week period.

Researchers at Mass General Brigham found that by December 2023, over one-third of all new prescriptions for type 2 diabetes ...

Novo Nordisk, the maker of Ozempic and Wegovy, has also jumped into the legal fight —this time by intervening in the OFA’s lawsuit against the FDA. The company supports the agency’s move to restrict ...